Sarepta shares yo-yo as FDA places hold on Duchenne trial Shares in Sarepta came under pressure after the biotech said it had temporarily halted a clinical trial of Share X Sarepta shares yo-yo as FDA places hold on Duchenne trial https://pharmaphorum.com/news/sarepta-shares-yo-yo-as-fda-places-hold-on-duchenne-trial/
Biogen and Happify partner on digital support for MS patients Digital health company Happify has signed a partnership with another biopharma company, joining forces with Biogen on a Share X Biogen and Happify partner on digital support for MS patients https://pharmaphorum.com/news/biogen-and-happify-partner-on-digital-support-for-ms-patients/
GSK pledges £1bn drive for infectious disease R&D GSK will invest around £1 billion ($1.2 billion) over a 10-year period to speed up R&D on infectious Share X GSK pledges £1bn drive for infectious disease R&D https://pharmaphorum.com/news/gsk-pledges-1bn-drive-for-infectious-disease-rd/
Novartis bags FDA okay for BRAF-positive tumour combination Novartis’ two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for Share X Novartis bags FDA okay for BRAF-positive tumour combination https://pharmaphorum.com/news/novartis-bags-fda-okay-for-braf-positive-tumour-combination/
Eisai’s brain health tool NouKNOW used in Tokyo dementia project Eisai’s digital tool to allow self-assessment of cognitive performance – NouKNOW – will be used in a Japanese Share X Eisai’s brain health tool NouKNOW used in Tokyo dementia project https://pharmaphorum.com/news/eisais-brain-health-tool-nouknow-used-in-tokyo-dementia-project/
Enanta lawsuit claims Pfizer’s Paxlovid infringes its patent US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid Share X Enanta lawsuit claims Pfizer’s Paxlovid infringes its patent https://pharmaphorum.com/news/enanta-lawsuit-claims-pfizers-paxlovid-infringes-its-patent/
Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Share X Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis https://pharmaphorum.com/news/precision-bio-climbs-on-near-1-5bn-sickle-cell-pact-with-novartis/
Moderna says COVID booster works against Omicron subvariants Moderna has reported top-line data suggesting that its COVID-19 booster vaccine candidate stimulates a strong immune response against Share X Moderna says COVID booster works against Omicron subvariants https://pharmaphorum.com/news/moderna-says-covid-booster-works-against-omicron-subvariants/
Pfizer is first big pharma to tap Truveta’s real-world data platform Pfizer has harnessed the expertise of health data specialist Truveta to provide close monitoring of safety and other Share X Pfizer is first big pharma to tap Truveta’s real-world data platform https://pharmaphorum.com/news/pfizer-is-first-big-pharma-to-tap-truvetas-real-world-data-platform/
Novartis faces threat of early generic of MS drug Gilenya in US Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after Share X Novartis faces threat of early generic of MS drug Gilenya in US https://pharmaphorum.com/news/novartis-faces-threat-of-early-generic-of-ms-drug-gilenya-in-us/
Moderna facility in UK confirmed, part of 10-year deal with gov’t Moderna has said it will open a new R&D and manufacturing facility in the UK which could lead Share X Moderna facility in UK confirmed, part of 10-year deal with gov’t https://pharmaphorum.com/news/moderna-facility-in-uk-confirmed-part-of-10-year-deal-with-govt/
Merck ups the stakes in pneumococcal jab face-off with Pfizer Dominance of the pneumococcal vaccine category is a race between Merck & Co and Pfizer, and while the Share X Merck ups the stakes in pneumococcal jab face-off with Pfizer https://pharmaphorum.com/news/merck-ups-the-stakes-in-pneumococcal-jab-face-off-with-pfizer/
AbbVie files Qulipta for chronic migraine prevention AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to Share X AbbVie files Qulipta for chronic migraine prevention https://pharmaphorum.com/news/abbvie-files-qulipta-for-chronic-migraine-prevention/
Single MRI-based brain scan could diagnose Alzheimer’s disease, says study Alzheimer’s disease could be diagnosed from a single MRI brain scan, according to a new study by Imperial Share X Single MRI-based brain scan could diagnose Alzheimer’s disease, says study https://pharmaphorum.com/news/single-mri-based-brain-scan-alzheimers-disease/
AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen Armed with new phase 3 data, AstraZeneca is preparing to file for regulatory approval of eplontersen, an antisense Share X AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen https://pharmaphorum.com/news/az-preps-fda-filing-for-3-6bn-amyloidosis-drug-eplontersen/
Alimetry nabs FDA okay for gastric disorder-diagnosing wearable New Zealand medical tech startup Alimetry has claimed an FDA approval for a wearable device that can be Share X Alimetry nabs FDA okay for gastric disorder-diagnosing wearable https://pharmaphorum.com/news/alimetry-nabs-fda-okay-for-gastric-disorder-diagnosing-wearable/
AbbVie’s Skyrizi beats IL-23 rivals to Crohn’s disease approval AbbVie’s IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into Share X AbbVie’s Skyrizi beats IL-23 rivals to Crohn’s disease approval https://pharmaphorum.com/news/abbvies-skyrizi-beats-il-23-rivals-to-crohns-disease-approval/
Pfizer takes stake in French Lyme disease jab partner Valneva Pfizer has acquired an 8.1% stake in French vaccines developer Valneva at a cost of €90.5 million (around Share X Pfizer takes stake in French Lyme disease jab partner Valneva https://pharmaphorum.com/news/pfizer-takes-stake-in-french-lyme-disease-jab-partner-valneva/
Understanding the True Impact of the COVID-19 Pandemic on the Immunocompromised Share X Understanding the True Impact of the COVID-19 Pandemic on the Immunocompromised https://pharmaphorum.com/partner-content/understanding-the-true-impact-of-the-covid-19-pandemic-on-the-immunocompromised/
An introduction to case report forms Share X An introduction to case report forms https://pharmaphorum.com/partner-content/an-introduction-to-case-report-forms/
Data-Led Digital KOL Engagement Share X Data-Led Digital KOL Engagement https://pharmaphorum.com/partner-content/data-led-digital-kol-engagement/
Measure your omnichannel maturity with our new tool Share X Measure your omnichannel maturity with our new tool https://pharmaphorum.com/partner-content/measure-your-omnichannel-maturity-with-our-new-tool/
AXON hires a Global Healthcare Insights and Strategy Lead Share X AXON hires a Global Healthcare Insights and Strategy Lead https://pharmaphorum.com/partner-content/axon-hires-a-global-healthcare-insights-and-strategy-lead/
Performance-io hires Lonneke Feskens to lead Europe Share X Performance-io hires Lonneke Feskens to lead Europe https://pharmaphorum.com/partner-content/performance-io-hires-lonneke-feskens-to-lead-europe/
